Joles J A, van Goor H, Koomans H A
Department of Nephrology and Hypertension, Faculty of Medicine, Utrecht University, The Netherlands.
Kidney Int. 1998 Apr;53(4):862-8. doi: 10.1111/j.1523-1755.1998.00825.x.
Progression of chronic renal disease is usually more rapid in males, both in humans and in experimental animals. Estrogen-replacement studies indicate that this may be related to the beneficial effects of estrogen on the lipoprotein profile. However, in hyperlipidemic analbuminemic rats (NAR), females are more prone to develop renal injury than males, and ovariectomy tends to decrease triglyceride levels and prevent renal disease. Therefore, we studied the effects of estrogen administration on lipoproteins, and the induction of renal injury in uninephrectomized female and male NAR. Ovariectomized and orchidectomized uninephrectomized NAR were treated with estradiol implants for 24 weeks. In an additional group of ovariectomized rats, the implant was removed after 12 weeks. Both in ovariectomized and orchidectomized NAR, estradiol caused severe hypercholesterolemia (9 to 12 mmol/liter) and hypertriglyceridemia (6 to 8 mmol/liter) after six weeks. Subsequently, these rats developed severe proteinuria, reaching 209 +/- 25 and 95 +/- 43 mg/day, respectively, after 24 weeks. At this point there was severe glomerular sclerosis, with a respective score of 107 +/- 21 and 61 +/- 33. In terminal blood samples the most pronounced increase in lipid levels were observed in very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL) and low density lipoproteins (LDL). In contrast, ovariectomized NAR and orchidectomized NAR without exogenous estrogen had much lower lipid levels (cholesterol 5 to 7 mmol/liter and triglycerides 1 to 2 mmol/liter) after six weeks. These rats, or ovariectomized NAR where the estrogen treatment had been withdrawn, had practically no proteinuria (4 +/- 1, 19 +/- 11, and 13 +/- 4 mg/day, respectively) or renal damage (glomerulosclerosis score 1 +/- 0.4, 5 +/- 3 and 3 +/- 1, respectively) after 24 weeks. Thus, in hypertriglyceridemic analbuminemic rats, estrogen-treatment causes further increases in both triglycerides and cholesterol. Most probably these changes contribute to the development of renal injury by estrogen in this model. This effect of estrogen, which has also been observed in the Zucker rat, is unique for the hypertriglyceridemic state and deserves further study.
在人类和实验动物中,慢性肾病的进展在男性中通常更快。雌激素替代研究表明,这可能与雌激素对脂蛋白谱的有益作用有关。然而,在高脂血症无白蛋白血症大鼠(NAR)中,雌性比雄性更容易发生肾损伤,卵巢切除术往往会降低甘油三酯水平并预防肾病。因此,我们研究了给予雌激素对脂蛋白的影响,以及对单侧肾切除的雌性和雄性NAR诱导肾损伤的情况。对单侧肾切除的卵巢切除和睾丸切除的NAR用雌二醇植入物治疗24周。在另一组卵巢切除的大鼠中,植入物在第12周后取出。在卵巢切除和睾丸切除的NAR中,六周后雌二醇均导致严重的高胆固醇血症(9至12毫摩尔/升)和高甘油三酯血症(6至8毫摩尔/升)。随后,这些大鼠出现严重蛋白尿,24周后分别达到209±25和95±43毫克/天。此时存在严重的肾小球硬化,评分分别为107±21和61±33。在终末血样中,在极低密度脂蛋白(VLDL)、中间密度脂蛋白(IDL)和低密度脂蛋白(LDL)中观察到脂质水平最明显的升高。相比之下,六周后,未接受外源性雌激素的卵巢切除NAR和睾丸切除NAR的脂质水平要低得多(胆固醇5至7毫摩尔/升,甘油三酯1至2毫摩尔/升)。这些大鼠,或已停止雌激素治疗的卵巢切除NAR,24周后几乎没有蛋白尿(分别为4±1、19±11和13±4毫克/天)或肾损伤(肾小球硬化评分分别为1±0.4、5±3和3±1)。因此,在高甘油三酯血症无白蛋白血症大鼠中,雌激素治疗会导致甘油三酯和胆固醇进一步升高。在这个模型中,这些变化很可能促成了雌激素导致的肾损伤的发展。雌激素的这种作用在Zucker大鼠中也有观察到,对于高甘油三酯血症状态来说是独特的,值得进一步研究。